Granisetron Fresenius Kabi

Granisetron Fresenius Kabi, containing the active ingredient granisetron hydrochloride, is an injectable intravenous formulation marketed in the European Union. It belongs to the 5‑HT3 receptor antagonist class and is prescribed as an antiemetic to help prevent nausea and vomiting associated with chemotherapy and postoperative recovery. The product is available by prescription and is not a controlled substance. It is supplied as a solution for intravenous infusion and is stored refrigerated.

Granisetron Fresenius Kabi is indicated for the prevention of nausea and vomiting in specific clinical settings.

- Prevention of chemotherapy‑induced nausea and vomiting (CINV). - Prevention of postoperative nausea and vomiting (PONV). - May be used as part of a prophylactic antiemetic regimen for patients receiving highly emetogenic chemotherapy. - Can be administered before surgical procedures to reduce the risk of postoperative emesis. - May be combined with other antiemetic agents such as dexamethasone for enhanced efficacy.

The safety profile of Granisetron Fresenius Kabi includes both common and less frequent adverse reactions.

Common: - Headache. - Constipation. - Dizziness or light‑headedness. - Fatigue or weakness. - Diarrhea. - Mild injection‑site discomfort or erythema.

Serious: - Allergic reactions including anaphylaxis, rash, or angioedema. - QT interval prolongation on electrocardiogram. - Cardiac arrhythmias, especially in patients with pre‑existing heart conditions. - Severe hypotension. - Serotonin syndrome, particularly when combined with serotonergic drugs. - Significant hepatic dysfunction or liver enzyme elevations.

Clinicians should consider several precautions when prescribing Granisetron Fresenius Kabi.

- Use with caution in patients with known cardiac conduction abnormalities or a history of prolonged QT interval. - Assess hepatic and renal function, as impairment may affect drug clearance. - Pregnancy category is unknown; avoid use unless the potential benefit justifies the risk. - Monitor for signs of hypersensitivity during and after infusion. - Avoid concurrent use of other QT‑prolonging agents when possible. - Adjust dosing in elderly patients if clinically indicated.

Granisetron Fresenius Kabi can interact with other medications, requiring attention to avoid adverse effects.

Avoid: - Concomitant use with other 5‑HT3 antagonists (e.g., ondansetron) due to additive effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that may increase granisetron plasma levels. - Drugs known to prolong the QT interval (e.g., certain antiarrhythmics, antipsychotics).

Use with caution: - Other antiemetics such as metoclopramide or dexamethasone. - Anesthetic agents that may affect cardiac conduction. - Serotonergic agents (e.g., SSRIs) in patients at risk for serotonin syndrome.